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Oriented attachment of VNAR proteins,
via site-selective modification, on PLGA–PEG
nanoparticles enhances nanoconjugate
performance†
Joa˜o C. F. Nogueira,a Michelle K. Greene,b Daniel A. Richards,ac
Alexander O. Furby,a John Steven,de Andrew Porter,de Caroline Barelle,*de
Christopher J. Scott *b and Vijay Chudasama *af
Herein we report the construction of a nanoparticle-based drug
delivery system which targets a key regulator in tumour angiogenesis.
We exploit a Variable New Antigen Receptor (VNAR) domain, conju-
gated using site-specific chemistry, to direct poly lactic acid-co-
glycolic acid–polyethylene glycol (PLGA–PEG) nanoparticles to delta
like canonical Notch ligand 4 (DLL4). The importance of site-specific
chemistry is demonstrated.
Over the last few years the utilisation of nanotechnology within
biomedicine, particularly in the field of targeted therapy, has
grown considerably.1,2 Nanoscale materials can cross biological
barriers including the blood–brain barrier,3 transit in and out
of blood vessels4 or even passively penetrate the cell membrane
by different mechanisms (e.g. endocytosis).5 Furthermore,
nanoparticles (NPs) are able to safely transport different types
of cargo, such as molecular imaging agents or cytotoxic drugs
in high quantities.6 Most recently, NPs have also been com-
bined with targeting proteins, such as antibodies or antibody
fragments, to enable the targeting of disease biomarkers in a
concept tagged ‘‘active targeting’’.7 Although antibodies have
been employed for the generation of actively targeted NPs, the
clinical application of the resultant nanoconjugates has
remained rare. This is due in part to suboptimal methods for
the appendage of proteins to NPs.8 For instance, many protocols
employ random conjugation methods, such as electrostatic
adsorption of proteins to NP surfaces, to achieve targeting.9
This method is mediated by the surface charge of antibodies,
which varies significantly from antibody to antibody, and can
lead to significant batch-to-batch variability of resulting nano-
conjugates and poor stability.10,11 To overcome these issues,
methods which rely on chemically stable covalent bonds to
graft antibodies to NPs have been developed; these methods are
reported to confer better stability in vivo.12 Early developers
focused on covalently attaching antibodies (via surface lysine
residues) to NP via carbodiimide chemistry.13–15 However, this
is sub-optimal as it usually presents low reaction efficiencies in
aqueous conditions due to competing hydrolysis.16 Conjointly,
the modification of lysine residues affords very little control
over the orientation of the antibody targeting ligands on the NP
surface, limiting antigen-binding and overall target avidity. We
recently demonstrated the importance of controlled chemical
ligation for successful nanoconjugate performance, particularly
in the context of target affinity.17a This study showed that using
site-selective chemistry to conjugate Trastuzumab antibody
fragments (i.e. F(ab)s) to PLGA–PEG NPs resulted in superior
antigen binding when compared to using classical lysine-based
approaches.17a
There is a growing trend in NP construction towards utilising
small antibody fragments rather than full antibodies as active
targeting ligands.18 Smaller size permits a greater loading on NP
surfaces, whilst maintaining the antigen-binding capability of a
full antibody, and absence of a fragment crystallisable (Fc) region
can reduce Fc-mediated immunogenicity.18–20 Methods of gener-
ating antibody fragments are well described in literature, e.g.
F(ab)0 and F(ab) (both ca. 50 kDa) can be generated through
enzymatic digestions,18 and have been successfully employed in
the formation of nanoconjugates for the treatment of multiple
diseases.17a,21,22 However, there is a drive to find alternative
proteins that share the same specific binding properties of
antibodies but that are of an even smaller size. Shark Variable
New Antigen Receptors (VNARs), at only ca. 11 kDa, are seen as an
attractive alternative to current traditional antibodies and their
fragments as they hold many advantages such as higher stability,
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solubility and low cost of manufacturing, while upholding
high specificity to bind to novel or cryptic epitopes.23–25 Most
relevantly, the simple VNAR molecular architecture presents a
versatile platform for re-formatting and engineering. For instance,
VNARs have been previously engineered to increase their solubility
and refolding ability26 and also to bind to many different antigens
with high specificity.27 Also, VNARs are reported to tolerate extreme
pH values (down to pH 1.5) and high temperature conditions.
These advantages have allowed the facile generation of a plethora
of new biologics.28 However, their applications within nano-
technology remain to be exploited.
Herein is presented a novel PLGA–PEG NP–VNAR conjugate
that targets the inhibition of endothelial sprouting and prolif-
eration (processes involved in tumour angiogenesis).29 We
hypothesised that by applying a highly-directed chemical
strategy for decorating nanocarriers with VNAR ligands, the over-
all potential of VNAR directed nanocarriers could be maximised,
i.e. antigen binding enhancement due to the favourable orienta-
tion and large number of proteins packed on the NP surface. To
ensure modularity, we created a platform that is amenable to
commonly employed and well-tolerated copper (Cu)-free ‘‘click’’
chemistry, namely strain-promoted azide–alkyne cycloaddition
(SPAAC) chemistry.
PLGA–PEG polymeric NPs were chosen as the nanocarrier
platform due to their well-established ability to effectively hold
cargo for controlled drug delivery.17a However, we anticipate
that the findings of this study could be extrapolated to
emerging nanocarriers e.g. poly(e-caprolactone)–PEG, which
recent findings have suggested could be ideal drug carriers
due to excellent cellular internalization and prolonged blood
circulation time.17b,c Owing to our past experience in synthesiz-
ing such PLGA–PEG constructs we used a 75 : 25 blend of
PLGA-502H : PLGA–PEG-azide to formulate our NP-azide con-
structs for ‘‘click’’ modification, as these NPs exhibit long-term
stability.17a
Subsequently, an anti-DLL4 E4 VNAR clone, hereafter
referred to as VNAR E4 6, was used as a model VNAR targeting
moiety. VNAR E4 6 clone was specifically expressed to recognise
and bind to DLL4, a key regulator that activates Notch signaling
pathways directly related with early embryonic vascular develop-
ment in tumor angiogenesis (see ESI,† for details).30 An
Alanine–Cysteine–Alanine (ACA) sequence was inserted at the
C-terminal region, enabling site-selective cysteine modifica-
tion. Also, this reactive cysteine thiol handle was inserted distal
from the antigen binding site, at the N-terminus, in view of
maximising orientation benefits and minimising any distur-
bance of the paratope–epitope interaction. To site-selectively
modify VNAR E4 6 and introduce a strained alkyne moiety we
synthesised monobromopyridazinedione 5. Bromopyridazine-
diones are selectively reactive towards cysteine-bearing pro-
teins, and bicyclo[6.1.0]nonyne (BCN(endo)) (BCN) is well
suited to ‘‘click’’ reactions with azide-bearing NPs in aqueous
buffers.31 Synthesis of strained alkyne monobromopyridazine-
dione (PD 5) proceeded from readily available starting materials
in a facile manner over five steps (Scheme 1).32 Initially, di-Boc
protection of methyl-hydrazine 1 and subsequent Michael
addition to tert-butyl acrylate yielded hydrazine 2. Following
this, deprotection and dehydration under acidic conditions
afforded acid PD 3. Subsequent esterification of acid 3 with
NHS afforded amine-reactive PD 4. In the final step, an amide
coupling between commercially available BCN(endo)–PEG2–NH2
and PD 4 yielded the desired heterobifunctional PD linker 5
(Scheme 1).
Bioconjugation of native VNAR E4 6 with PD 5 was appraised
via SDS-PAGE and LC-MS, where it was observed that complete
conversion only occurred following pre-reduction of VNAR E4 6
with tris(2-carboxyethyl)phosphine (TCEP). This can be explained
by the fact that the single cysteine can be capped with glutathione
or even spontaneously form a disulfide dimer in solution. Several
optimisation parameters were tuned to obtain pure VNAR conju-
gate 7 (see ESI,† for details). The optimised conditions for
successful site-selective modification comprised pre-incubation
of VNAR E4 6 with TCEP (10 eq.), followed by addition of PD 5
(20 eq.); full reduction and complete conversion were con-
firmed by LC-MS. To demonstrate the availability of VNAR
conjugate 7 to participate in a ‘‘click’’ reaction, the construct
was successfully reacted with Alexafluors-488-N3 (Scheme 2,
conjugate 8). Having successfully modified the C-terminal
cysteine residue of the VNAR E4 with PD 5, we next aimed to
couple the protein to the surface of polymeric azide NPs in a
site-selective manner. Previously, we have shown that similar
heterobifunctional linkers can be introduced into antibody
F(ab) fragments, thereby facilitating site-specific ‘‘click’’
Scheme 1 Synthesis route of PD 5. Reagents and conditions: (i) Boc
anhydride, i-PrOH, DCM, 21 1C, 16 h; (ii) tert-butyl acrylate, i-PrOH,
60 1C, 24 h; (iii) bromomaleic acid, AcOH, reflux, 5 h; (iv) DCC, NHS,
THF, 21 1C, 16 h, (v) BCN(endo)–PEG2–NH2, MeCN, 21 1C, 16 h.
Scheme 2 Bioconjugation of VNAR E4 6 with PD 5 and subsequent ‘‘click’’
reaction with Alexafluors-488-N3. Reagents and conditions: (vi) TCEPHCl
(10 eq.), PD 5 (20 eq.), phosphate buﬀer pH 7.4, 21 1C, 16 h. (vii)
Alexafluors-488-N3, phosphate buﬀer pH 7.4, 21 1C, 5 h.
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conjugation to complementary azide-functionalised PLGA–PEG
NPs of approximately 200 nm in diameter (Table S1, ESI†).17a In
concert with this strategy, the strained alkyne functionality of
VNAR conjugate 7 was reacted with surface-exposed azide groups
on PLGA–PEG-azide NP 10 via Cu-free SPAAC chemistry to
generate E4 functionalised NP (site-selective cysteine modified
E4 NP 12) of 214.2  13.3 nm in size (Fig. 1 and Table S1, ESI†).
A benchmark formulation was also included in this study to
allow direct comparison of our coupling strategy with carbo-
diimide chemistry; an established nanoconjugation approach that
has been widely implemented in the development of targeted NP
modules. Here, amine groups distributed throughout native VNAR
E4 6 (i.e. containing no PD 5 linker) were reacted with NHS esters
on the surface of PLGA–PEG–NHS NP 9, with coupling proceeding
via amide bond formation to generate a nanoconjugate of
197.8  5.1 nm in size (random lysine modified E4 NP 11).
Interestingly, the conjugation efficiency was revealed to be
greater for the SPAAC click chemistry when compared to the
control; this is in agreement with our previously reported
data.17a Also, non-targeted NHS and azide NP controls were
utilised, of 191.5  5.3 nm and 194.0  2.5 nm in size,
respectively (NHS NP 9 and azide NP 10). To confirm that VNAR
E4 still retained its antigen binding affinity after chemical
manipulation and nanoconjugation, fluorescently labelled
NPs conjugated to VNAR E4, i.e. 11 and 12, were incubated
with recombinant human DLL4 immobilised on microtiter
plates. Dose-dependent binding of NP 12 to DLL4 was observed,
with each increment in NP concentration leading to a
stepwise enhancement in fluorescence (Fig. 2). Despite similar
concentration-dependent binding of NP 11 to DLL4, fluores-
cence readouts were significantly lower than those observed for
NP 12. The controls showed the binding of non-targeted control
NPs (i.e. NPs 9 and 10) to be negligible. Moreover, to confirm
that the enhanced binding of NP 12 was not simply due to the
higher protein loading on these NP, we next formulated NP 11
and NP 12 to present equal amounts of VNAR E4 6 and VNAR
conjugate 7, respectively, on their surfaces. Again, DLL4 bind-
ing by NP 12 remained superior (Fig. S3, ESI†). Collectively,
these findings demonstrate that our novel chemistry may
be exploited for the site-specific ‘‘click’’ conjugation of DLL4-
targeted VNARs to polymeric NPs, yielding nanoconjugates with
superior binding ability than those formulated using conven-
tional methods.
Following this, we sought to verify that the observed
enhancement in fluorescence in the above binding assays was
attributed to specific interactions between the targeted nano-
formulations and the immobilised DLL4 antigen. To do this,
the E4 paratopes on the surface of the NP were saturated with
an excess of free DLL4 prior to incubation in microtiter plate
wells coated with the same antigen. Binding of NP 11 and 12
was inhibited following pre-incubation with DLL4, as evidenced
by significantly lower fluorescence readouts for these samples
(Fig. 3A). As an alternative approach, both NP 12 and an anti-
DLL4 monoclonal antibody were added simultaneously to
DLL4-immobilised wells. In these studies, NP binding was
progressively impeded with increasing concentrations of
competing anti-DLL4 (Fig. 3B). Taken together, these experi-
ments provide robust confirmation that the ability of the NP
formulations to bind to DLL4 was dependent upon the surface
conjugation of the VNAR proteins.
We next investigated whether the superior binding of site-
selective cysteine modified E4 NP 12 was contingent upon both
surface display of azide and cysteine modification of the VNAR.
Various nanoformulations were synthesised by incubating
strained alkyne bearing VNAR conjugate 7 with NP comprised
solely of PLGA-502H, or a blend of PLGA-502H and either
PLGA–PEG–NHS or PLGA–PEG-azide. Binding of these NP to
immobilised DLL4 was minimal, except for those formulated
via ‘‘click’’ coupling of VNAR conjugate 7 to complementary
azide-terminated NP (Fig. 3C). Furthermore, native VNAR E4 6
was also incubated with the above polymeric NP formulations;
all three formulations showed only marginal levels of DLL4
binding (Fig. 3C). These findings clearly indicate that the
enhanced DLL4 binding activity of NP 12 is not simply
mediated via non-specific surface adsorption of the VNAR clone.
Fig. 1 Representation of all nanoformulations tested: NHS NP 9; azide NP
10; random lysine modified E4 NP 11 and site-selective cysteine modified
E4 NP 12.
Fig. 2 Binding of site-selective cysteine modified E4 NP 12 to DLL4 is
greatly enhanced compared to random lysine modified E4 NP 11. Binding
of fluorescently labelled NPs 11 & 12, and corresponding blank NP controls
9 & 10 (125, 250 and 500 mg polymer mL1) to DLL4 was analysed by
modified ELISA. Data expressed as mean  SEM.
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Rather it shows that the presence of the surface-exposed azide
and the strained-alkyne modified VNAR are critical determi-
nants of nanoconjugate performance. This confirms the site-
selectivity and importance of covalent conjugation.
As a final set of studies, we explored the impact of diﬀerent
loadings of strained alkyne bearing VNAR conjugate 7 on the
surface of the NP. As expected, incremental addition of VNAR
conjugate 7 resulted in cumulative improvements in DLL4
binding. Interestingly, fluorescence levels plateaued upon add-
ing 42 nanomoles of VNAR conjugate 7 per milligram of
polymer, suggesting epitope saturation (see Fig. S4, ESI†).
In conclusion, this study showcases a new modular method
for attaching VNAR proteins onto the surfaces of PLGA–PEG
polymeric NPs via ‘‘click’’ chemistry. A novel heterobifunctional
PD linker was designed to enable site-selective cysteine
modification of a VNAR clone that was attached to an azide
decorated NP via SPAAC conjugation. This NP–VNAR construct,
with orientated protein presentation on the NP surface, showed
favourable properties in terms of target binding when com-
pared to traditional NP–protein conjugation chemistries.
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fluorescently labelled NP composed of (1) PLGA-502H, (2) a 75 : 25 blend
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modified ELISA. Data expressed as mean  SEM.
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